Benefits of Supplementing a GLP-1 Type Medication With Physical Activity

Area of Science:

• Metabolic Health
• Pharmacology
• Public Health

Background:

• Obesity affects over 100 million US adults, presenting complex metabolic and genetic challenges to weight management.
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly sought for weight loss and health improvement.
• Physiological changes in obesity complicate metabolic processes and gene expression, hindering weight loss efforts.

Purpose of the Study:

• To highlight the synergistic benefits of combining GLP-1 RA medications with physical activity (PA).
• To emphasize the importance of concurrent prescription of PA with GLP-1 RAs by healthcare professionals.
• To advocate for equitable access to GLP-1 RAs and PA through improved insurance and employer benefit designs.

Main Methods:

• Literature review on the combined effects of GLP-1 RAs and PA on metabolic health.
• Analysis of health outcomes associated with concurrent use of GLP-1 RAs and PA.
• Examination of current healthcare and insurance policies regarding access to obesity treatments.

Main Results:

• GLP-1 RA and PA combination yields synergistic effects, improving blood glucose, blood pressure, and lipid management.
• This combination enhances body composition and reduces overall cardiometabolic risk.
• Concurrent PA can mitigate some risks associated with GLP-1 RA monotherapy.

Conclusions:

• Healthcare providers should routinely prescribe physical activity alongside GLP-1 receptor agonists when clinically appropriate.
• Addressing disparities in access requires commitment from insurance carriers, employers, and advocates for comprehensive benefit design.
• Integrated treatment strategies are crucial for effectively managing obesity and its associated health risks.